Velcade

Velcade

  • August 2018 •
  • 31 pages •
  • Report ID: 5779935 •
  • Format: PDF
Drug Overview
Velcade (bortezomib; Takeda/Johnson and Johnson) is an intravenously or subcutaneously administered 26S proteasome inhibitor that affects multiple signaling cascades and induces cell death. In preclinical studies, Velcade has been shown to induce apoptosis and sensitize tumor cells to chemotherapy or radiation.